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Germ-line mutations in PALB2 lead to a familial predisposition to
breast and pancreatic cancer or to Fanconi Anemia subtype N. PALB2
performs its tumor suppressor role, at least in part, by supporting
homologous recombination-type double strand break repair (HR-
DSBR) through physical interactions with BRCA1, BRCA2, and
RAD51. To further understand the mechanisms underlying PALB2-
mediated DNA repair and tumor suppression functions, we targeted
Palb2 in themouse. Palb2-deﬁcientmurine ES cells recapitulated DNA
damage defects caused by PALB2 depletion in human cells, and germ-
line deletion of Palb2 led to early embryonic lethality. Somatic de-
letion of Palb2 driven by K14-Cre led to mammary tumor formation
with long latency. Codeletion of both Palb2 and Tumor protein 53
(Trp53) accelerated mammary tumor formation. Like BRCA1 and
BRCA2 mutant breast cancers, these tumors were defective in
RAD51 focus formation, reﬂecting a defect in Palb2 HR-DSBR func-
tion, a strongly suspected contributor to Brca1, Brca2, and Palb2
mammary tumor development. However, unlike the case of Brca1-
mutant cells, Trp53bp1 deletion failed to rescue the genomic insta-
bility of Palb2- or Brca2-mutant primary lymphocytes. Therefore,
Palb2-driven DNA damage control is, in part, distinct from that exe-
cuted by Brca1 and more similar to that of Brca2. The mechanisms
underlying Palb2mammary tumor suppression functions can nowbe
explored genetically in vivo.
mouse model | familial breast cancer
Partner and Localizer of BRCA2 (PALB2) is a breast cancersusceptibility gene. Its product was identiﬁed as a major in-
teracting protein of the BReast CAncer susceptibility gene pro-
duct 2, BRCA2 (1). This interaction is required for the repair of
DNA double strand breaks (DSBs) by homologous recombination
(HR) because PALB2 is necessary for the chromatin association
of BRCA2 and its partner, RAD51 (1). RAD51 is the central
recombinase in HR, and it participates in D-loop formation and
strand displacement (2). PALB2 also plays a BRCA2-independent
role in the HR process by enhancing RAD51 function (3, 4).
PALB2 interacts with both BRCA1 and BRCA2 and mediates
the long-known interaction between these proteins (5, 6). Loss
of PALB2 does not affect BRCA1 recruitment to irradiation-
induced foci (IRIF) but abrogates colocalization of BRCA2 and
RAD51 at these structures (1, 5). Genetic analyses have shown
that, like BRCA2, a member of Fanconi anemia complementation
group D1, PALB2 is also the Fanconi anemia complementation
group N protein (FANCN) (7, 8). PALB2 is also a breast cancer
suppressor protein in its own right (9–12). Unlike BRCA1 and
BRCA2 mutant tumors, only some PALB2-associated breast can-
cers have undergone loss of PALB2 heterozygosity (LOH) (9, 10).
This ﬁnding implies that a reduction of PALB2 gene copy number
might be sufﬁcient to allow breast cancer development in some,
but not all, settings. Why this difference exists is an open question.
Breast cancer in PALB2-mutated families is of intermediate
penetrance, unlike that in BRCA1/2 families (10, 12). Although
PALB2 mutations are rarer than BRCA1/2 mutations, available
clinical data suggest that heterozygous, germ-linePALB2mutations
do not precisely phenocopy either BRCA1 or BRCA2 cancer pre-
disposition syndromes (9, 10). This ﬁnding is consistent with the
notion that PALB2 biological functions extend beyond simply en-
abling BRCA1–BRCA2 complex formation. PALB2 also interacts
with MRG15 (also known as MORF4L1) (13), a subunit of histone
acetyl transferase/deacetylase complexes, and with KEAP1, a major
regulator of the antioxidant transcription factor NRF2 (also known
as NFE2L2) (14). In addition, PALB2 contains a highly conserved,
chromatin-associated domain (ChAM) for which no binding part-
ners are known (15). The contribution of these PALB2 binding
partners and of the ChAM domain to the BRCA1-PALB2-BRCA2
HR machinery and/or to PALB2’s cancer suppression function is
unclear. Thus, it is conceivable that PALB2 exerts multiple func-
tions that extend beyond its known role in HR-mediated double
strand break repair.
To date, it has been difﬁcult to study the molecular pathogen-
esis of PALB2 breast cancer in detail because of the lack of a ge-
netically engineered mouse model that recapitulates the human
disease. Thus, we have generated a model of Palb2 breast cancer
in the mouse and have documented its most salient properties. An
analogous model was recently generated by others (16).
Results and Discussion
Targeting the Mouse Palb2 Gene and Generation of Palb2-Deﬁcient
ES Cells. To generate a Palb2 allele that could be conditionally
inactivated upon Cre recombinase expression, we inserted loxP
sites ﬂanking exons 2 and 3 of the Palb2 gene (Fig. S1 A and B).
These exons encode a putative nuclear localization signal se-
quence and the PALB2 coiled-coil domain (Fig. 1A, Fig. S1A).
The latter mediates the PALB2 interaction with BRCA1 (5, 6).
Deletion of these exons would result in out-of-frame reading of
exon 4 and premature termination of the PALB2 translation
before the BRCA2-interacting, seven-bladed WD40-type β-pro-
peller domain (Fig. 1A, Fig. S1A). Due to premature truncation
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of the Palb2 ORF, the resulting transcript is also a candidate for
degradation via nonsense-mediated decay.
Targeting of the Palb2 locus and integration of both loxP re-
combination sites was conﬁrmed by Southern blot analysis (Fig.
S1C). Heterozygous ES cells (Palb2neo/+) were injected into
blastocysts, and the resulting chimeras from two individual clones
were bred to either Flp-deleter mice (to eliminate the Frt-ﬂanked
neomycin resistance cassette and generate a conditional allele) or
Cre-deleter mice (to generate a conventional Palb2 KO allele).
Germ-line transmission of the Palb2neo allele occurred from nearly
all chimeras, and mice were successfully genotyped for the Flp-
and the Cre-recombined alleles (Palb2ﬂ or Palb2−, respectively).
We attempted to derive ES cells from the Palb2− allele. Three,
independent Palb2 ES cell lines were derived from a single, het-
erozygous Palb2ﬂ/− cross. Expression analysis of Palb2 mRNA by
quantitative real-time RT-PCR (qRT-PCR) conﬁrmed that one of
these ES lines was Palb2ﬂ/ﬂ and the other two were Palb2−/− (Fig.
S1D). The loss of full-length Palb2 expression from these lines was
further conﬁrmed by Western blotting, using a polyclonal anti-
mouse PALB2 antibody raised against the N-terminal 200 residues
of the mouse PALB2 protein (Fig. 1B). Therefore, Palb2 loss did
not prevent ES cell derivation and subsequent survival. The three
ES cell lines we derived were morphologically comparable, pro-
liferated at the same rate as wild-type (WT) ES cells and were
capable of differentiation into embryoid bodies.
ES cells that are deﬁcient for Brca1 or Brca2 have been noto-
riously difﬁcult to isolate and are severely compromised in their
proliferation (17, 18). In keeping with these ﬁndings, Palb2−/− ES
cells could not be derived from embryos carrying a conventional
PALB2 gene-trap allele (19). Because PALB2 operates immedi-
ately upstream of BRCA2 and is required for BRCA2 localization
at DNA double strand breaks, it is possible that the viability and
robustness of our Palb2−/−ES cells were due to residual expression
of a truncated PALB2 species. Such a polypeptide could, in theory,
result from translation initiation downstream of the engineered
Palb2 genomic deletion. No such truncated protein was detected
with our polyclonal antibody (Fig. 1B).
To test whether the conditional gene targeting approach that
was used had generated an allele that would be rendered null
after Cre action, the response of Palb2ﬂ/ﬂ and Palb2−/− ES cells to
DNA damaging agents that cause double strand breaks was an-
alyzed. Normally, exposure of PALB2-proﬁcient cells to ionizing
radiation (IR) leads to the formation of phosphorylated histone
H2A.X (γH2AX) nuclear foci and subsequent recruitment of
BRCA1, BRCA2, and RAD51 to these structures. As expected,
after exposure to IR, γH2AX and BRCA1 IRIF formation was
unaffected in Palb2−/− cells (Fig. 1C, Fig. S2A). However, the
recruitment of RAD51 was severely compromised (Fig. 1C). This
defect was also evident at the biochemical level because no in-
crease in chromatin loading of RAD51 after IR could be detected
in nuclear extracts of IR-treated Palb2−/− cells (Fig. 1D).
Because biallelic PALB2 mutations in humans cause Fanconi
anemia, a hallmark of which is increased sensitivity to DNA cross-
linking agents such as mitomycin C (MMC), the sensitivity of
Palb2−/− ES cells to MMC as well other DNA damaging agents
was assayed. Both Palb2−/− ES lines displayed increased sensitivity
to MMC, IR, and the radiomimetic drug, neocarzinostatin (Fig.
1E, Fig. S2 B and C). These ﬁndings further imply that these
Palb2−/− cells are functional KOs for Palb2 because they are
compromised in multiple, known Palb2-associated functions.
Thus, upon Cre-mediated recombination in vivo, the afore-
mentioned conditional Palb2 allele appears to be converted to
a Palb2-null allele.
Loss of Palb2 in the Germ Line Results in Early Embryonic Lethality.
Germ-line deletion of Brca1 or Brca2 results in early embryonic
lethality (17, 20, 21). Although Palb2−/− ES cells displayed no
apparent growth defects compared with Palb2ﬂ/ﬂ controls, Palb2
loss could still be deleterious in differentiated progeny cells, and
thereby negatively affect mouse development. Indeed, we were
unable to obtain Palb2−/− mice from heterozygous crosses (Fig.
S3A), consistent with previous reports (19, 22). Dissection of
embryos from timed pregnancies revealed that Palb2-null em-
bryos could be recovered only up to E12.5, but even then at sub-
Mendelian ratios. These embryos repeatedly exhibited severe
malformations. At earlier time points, morphological aberrations
of Palb2−/− embryos were less obvious. However, these mutant
embryos were clearly smaller than WT or heterozygous litter-
mate embryos (Fig. S3B), and some displayed exencephaly as
well as malformations of the placental labyrinth and yolk sac-
associated blood islets (Fig. S3 C–F). The fact that Palb2 nulli-
zygosity resulted in embryonic lethality detectable at E8.5–E10.5
is consistent with earlier reports showing that homozygous Palb2-
deﬁcient mice also die during embryogenesis at ∼E8.5 (19, 22).
Embryonic lethality due to loss of Brca1 or Brca2 can be
delayed by concomitant loss of P53 (encoded by Trp53) or the
CDK inhibitor p21 (encoded by the Cdkn1a gene) (23), (24).
Trp53 loss also delayed the lethality of Palb2 KO embryos, which
otherwise exhibited increased p21 abundance (22). We therefore
tested whether loss of p21 expression affects Palb2−/− embryonic
lethality by generating Palb2; Cdkn1a−/− embryos. As expected,
loss of p21 expression did delay embryonic lethality of Palb2 KO
embryos by 2–3 d (Fig. S3A). However, all Palb2/Cdkn1a double
KO embryos still displayed multiple malformations and impaired
growth compared with Palb2 heterozygous or WT littermates
Fig. 1. Conditional gene targeting of mouse Palb2. (A) Schematic represen-
tationof Palb2domains and the exons fromwhich theyare encoded. The yellow
area corresponds to the frameshifted ORF that results from recombination of
the inserted loxP recombination sites. (B) Western blot analysis for PALB2 iso-
lated in chromatin-enriched extracts (S420) of three independent ES cell lines.
The full-length mouse PALB2 protein is ∼120 kDa. A nonspeciﬁc background
band is indicated by an asterisk and can be used as an internal loading control.
(C) Recruitment of RAD51 to DSBs marked by γH2AX IRIF 2 h after exposure of
Palb2ﬂ/ﬂ and Palb2−/− ES cells to to 5 Gy of ionizing radiation (IR). (D) Western
blot analysis of chromatin-bound (S420) RAD51 in Palb2ﬂ/ﬂ and Palb2−/− ES cells
that received 10 Gy of IR and the respective unirradiated control cells. Histone
H3 was used as a loading control. (E) Dose–response curves of Palb2ﬂ/ﬂ and
Palb2−/−ES cells after exposure to increasing concentrations of neocarzinostatin.
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and were eventually resorbed. Therefore, these Palb2−/− em-
bryonic rescue effects were incomplete and failed to suppress
embryonic lethality.
Because the establishment of the placenta and onset of em-
bryonic hematopoiesis are critical steps in development that take
place around the time of lethality of Palb2 embryos, we asked
whether the lethality of Palb2 KO embryos could be bypassed by
a WT placenta. To this end, we used the Palb2ﬂ/ﬂ and Palb2−/−
ES cells we had generated to perform tetraploid complementa-
tion assays. In this assay, diploid KO ES cells are aggregated to
tetraploid WT blastocysts to generate KO embryos that are
supported by a WT placenta because the tetraploid WT blasto-
meres are still capable of forming a placenta but cannot con-
tribute to the embryo.
We found that embryos derived from the Palb2−/− ES cells
were already underdeveloped and malformed at E9.5 compared
with their Palb2ﬂ/ﬂ counterparts (Fig. S3 I and J). At E12.5, embryos
derived from Palb2ﬂ/ﬂ ES cells appeared normal whereas embryos
from Palb2−/− ES cells had been resorbed (Fig. S3 K and L).
Likewise, breeding of the Palb2ﬂ/ﬂ conditional allele to Meox2-
Cre knock-in (KI) mice (in which Cre is expressed from the
endogenous Meox2 locus only in the embryo proper and not in
the placenta or extraembryonic tissues) (25) only yielded viable
mice in which the Palb2 deletion was incomplete. Collectively,
these ﬁndings indicate that Palb2 is an essential gene during
development, and its deﬁciency in the embryo proper is in-
compatible with life. These ﬁndings are analogous to previous
results showing that the lethality of Brca1−/− embryos could not
be rescued by tetraploid complementation assay (20).
Palb2 Is a Breast Tumor Suppressor in Mice. To assess the effect of
Palb2 loss-of-function on mammary tumorigenesis, we crossed
Palb2ﬂ/ﬂ mice with keratin 14 promoter-driven Cre (K14-Cre)
transgenic mice (26). K14-Cre transgenic animals preferentially
express Cre recombinase in the basal epithelium of the mammary
ducts, as well as in skin and oral mucosa. K14-Cre has previously
been used to model murine Brca1 and Brca2 mammary tu-
morigenesis (27).
PALB2, like BRCA1 and -2, appears to be a breast cancer
suppressor in humans (9, 10, 28). Therefore, in an effort to de-
velop a tractable system for studying how Palb2 operates in this
regard, we set out to develop a Palb2mouse breast cancer model.
Mammary tumor formation initiated by BRCA1 or BRCA2 loss
requires concomitant loss of functional p53 (encoded by Trp53 in
mice) (27, 29). This observation was considered in efforts to
establish a Palb2 model.
We ﬁrst generated Palb2/Trp53 double conditional mice by
crossing Palb2ﬂ/ﬂ; K14-Cre transgenic mice with Trp53 conditional
mice. All mice that harbored the conditional alleles for Palb2 and/
or Trp53 in the absence of K14-Cre were phenotypically normal,
fertile, and capable of nursing their litters. During the period
of tumor monitoring (up to 600 d after birth), Trp53ﬂ/ﬂ; K14-Cre
female mice developed spontaneous mammary tumors with a fre-
quency of∼80%and amean tumor-free interval (T1/2) of 320 d. By
contrast, Palb2ﬂ/ﬂ; Trp53ﬂ/ﬂ; K14-Cre double conditional mice de-
veloped tumors much faster (T1/2 = 192 d, P = 2.4 × 10
−5), in-
dicating that Palb2 loss accelerates tumor formation on a Trp53-
null background (Fig. 2A). These latencies are comparable with
Brca2ﬂ/f; Trp53ﬂ/ﬂ; K14-Cre and Brca1ﬂ/ﬂ; Trp53ﬂ/ﬂ; K14-Cre mice
(T1/2 = 181 and 213 d, respectively) (27, 30).
Somatic loss of one Trp53 allele displayed, as expected,
a haploinsufﬁcient tumor suppressor phenotype (27, 30), given
that Palb2ﬂ/ﬂ; Trp53ﬂ/+; K14-Cre mice developed tumors signiﬁ-
cantly faster than Palb2ﬂ/ﬂ; Trp53+/+; K14-Cremice (T1/2 = 225 d vs.
420 d, respectively, P = 2.5 × 10−12, Fig. S4C). Palb2 loss of
function also accelerated tumor formation on a Trp53 hetero-
zygous (ﬂ/+) background, again reﬂecting the genetic interaction
of these two genes (Fig. 2B).
K14-Cre-mediated loss of Palb2 and Trp53 led, predominantly,
to tumor formation in breast, skin, and oral mucosa (Fig. 2E), as
previously reported for K14-Cre-driven Brca1 and Brca2 cancers
(27, 30–32). All of the mammary cancers were estrogen and
progesterone receptor (ER/PR)-negative, basal-like (Fig. S4 D–
F), much like the BRCA1 and -2 tumors generated by K14-Cre
(30, 32). Although most of the tumors found in Palb2+/+;Trp53ﬂ/ﬂ;
K14-Cre mice were breast carcinomas, Palb2/Trp53 compound
KO mice displayed an expanded spectrum of tissues affected by
tumors (Fig. 2E), suggesting that combined loss of PALB2 and
P53, possibly due to some expression of Cre in other tissues, also
results in tumor formation that is not restricted to the
mammary gland.
Mice harboring conditional alleles for Palb2 and Trp53, but no
K14-Cre transgene, and Palb2+/+; Trp53+/+; K14-Cre mice did not
display overt tumor formation during the observation period (Fig.
2C), despite the intrinsic mutagenic activity of Cre in mammalian
cells (31, 33). Therefore, tumor formation in the above-noted
experiments is a product of targeted gene deletion.
All tumors from Palb2ﬂ/ﬂ; Trp53ﬂ/ﬂ; K14-Cre mice (n = 12) had
lost both copies of Palb2 and Trp53 (Fig. 2D). Similarly, in all
tumors from Palb2ﬂ/ﬂ; Trp53ﬂ/+; K14-Cre mice (n = 15), the con-
ditional Palb2 and Trp53 alleles were recombined. The WT copy
of Trp53 was also lost in most tumors, probably through LOH.
Early reports describing a lack of PALB2 LOH in clinical tu-
mor samples from heterozygous patients suggested that PALB2
could be a haploinsufﬁcient tumor suppressor in humans
whereas other reports showed that multiple PALB2 tumors
revealed PALB2 LOH, implying that the PALB2 tumor forma-
tion process is not uniform (9, 34, 35). In our experimental set-
ting, no haploinsufﬁciency for tumor suppression was observed
for Palb2, as indicated by the comparable latency in Palb2ﬂ/+;
Trp53ﬂ/ﬂ; K14-Cre and Palb2+/+; Trp53ﬂ/ﬂ; K14-Cre tumor de-
velopment (P = 0.46, Fig. S4A). Similarly, when compared on
a Trp53ﬂ/+; K14-Cre background, cohorts of Palb2+/+ and Palb2ﬂ/+
mice developed tumors with similar latency and frequency (P =
Fig. 2. Tumor formation in Palb2ﬂ/ﬂ conditional mice. (A–C) Kaplan–Meier
curves display that Palb2 loss accelerates tumor formation both on a Trp53-
conditional null background (A), on a Trp53-conditional heterozygous back-
ground (B), and on a Trp53 WT background (C). (D) Gene dosages of Palb2
(Upper) and Trp53 (Lower) in mammary tumors derived from Palb2/Trp53 dou-
ble conditional mouse cohorts. The germ-line Palb2 and Trp53 genotypes of the
mice are indicated in red below the graphs. (E) Spectrum of tumors arising in
mouse cohorts with different combinations of Palb2 and Trp53 alleles. The
genotypes of the mice are shown above the graphs.
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0.96, Fig. S4B), implying that heterozygous Palb2 loss of function
did not contribute to tumor formation.
Moreover, Palb2 heterozygous mouse breast tumor lines dis-
played proper RAD51 localization at IRIF, consistent with
preserved HR function (see Fig. 4C). By contrast, Palb2−/−
breast tumor cell lines displayed the same defect in RAD51
accumulation observed in Palb2-null primary cells (see Fig. 4C).
These ﬁndings suggest a role for HR deﬁciency in the genesis of
Palb2 tumors, a state that is not compatible with retention of
a functional copy of the gene. Moreover, an analysis of tumors
that arose in Palb2ﬂ/+; Trp53ﬂ/ﬂ; K14-Cre mice implies that a sig-
niﬁcant fraction of these tumors retained at least one copy of
PALB2, suggesting that loss of one copy of the gene did not
contribute to tumor formation in this model (Fig. 2D).
Although we observed long latency tumors only in Palb2ﬂ/ﬂ;
K14-Cre mice on a WT Trp53 background (T1/2 = 420 d), tumor
formation was nonetheless highly signiﬁcant compared with
Palb2+/+; Trp53+/+; K14-Cre controls (P = 5.4 × 10−10, Fig. 2C).
The majority of these tumors were small lesions in the head and
neck, and a few were mammary tumors. All of these mammary
tumors were Palb2−/−, and all displayed either mutations in or
loss of Trp53 by LOH.
The ﬁnding that loss of Palb2 alone is sufﬁcient to induce long
latency tumor formation contrasts with most Brca1 and Brca2
mouse models in which signiﬁcant numbers of these tumors
could not be detected, unless Trp53 was codeleted (27, 30, 36,
37). One explanation for this ﬁnding is that somatic Palb2 loss
might be better tolerated than somatic Brca1/2 loss on a Trp53
WT background. This hypothesis ﬁts with the ﬁnding that Palb2
nullizygosity gives rise to a less severe phenotype in ES cells than
biallelic Brca1 or Brca2 loss (17, 18, 27, 38).
Genomic Features of Palb2/Trp53-Deﬁcient Mammary Tumors. Ge-
nomic instability is a hallmark of human cancer, and it promotes
tumor initiation and progression. Experimental mouse tumor
models have recapitulated this aspect of human tumorigenesis
(39). To gain insight into the genomic structures of the tumors
that arose due to the loss of Palb2, we performed high-resolution
comparative genomic hybridization (CGH) (40) analysis of
Palb2/Trp53, Brca1/Trp53, Brca2/Trp53, and Trp53 only-deﬁcient
mammary tumors that arose in K14-Cre mice (Fig. 3 A–C).
Segmentation analysis of the CGH data was performed for
each tumor to assess the number of genomic segments with de-
viating copy number changes (aka genomic segmentation), as
a readout of genomic instability (41). Palb2/Trp53 and Brca1/
Trp53 tumors displayed apparently greater genomic instability
(genomic segmentation) compared with Brca2/Trp53 and Trp53-
only tumors, but the difference was not statistically signiﬁcant.
However, when the relative dose of ampliﬁed segments (log2
dose ≥ 0.5) was analyzed, Palb2/Trp53 mammary tumors (n = 8)
displayed a signiﬁcantly higher average dose of ampliﬁed seg-
ments than either Brca1/Trp53 (n = 4; P < 0.0001, Fig. 3C) or
Brca2/Trp53 tumors (n = 5; P = 0.0014, Fig. 3C). The low
numbers of deletions (log2 dose ≤ -0.5) detected in Brca2/Trp53
and Trp53-only tumors precluded further analysis of this aspect
of genomic instability (Fig. 3B).
No signiﬁcant difference in focal genome ampliﬁcation appeared
when Palb2/Trp53 tumors were compared with Trp53-only tumors,
indicating that Palb2/Trp53 tumors share a similar ampliﬁcation-
prone genomic proﬁle with Trp53-only tumors, despite their
marked difference in tumor formation kinetics. The inability of
Palb2 loss to suppress focal genomic ampliﬁcations (unlike what
was observed in Brca1/Trp53 and Brca2/Trp53 tumors) could be
accounted for by three, alternative explanations.
First, these differences could be due to residual activity of the
conditional Palb2 allele we generated, and other Palb2 loss of
function mutations might trigger the formation of true Brca2
tumor phenocopies. Second, our allele is a functional null, as our
studies suggest, but complete loss of Palb2 is similar to a BRCA2
hypomorphic phenotype rather than a complete loss of BRCA2
function. Alternatively, there are PALB2 functions that are, at
least in part, nonoverlapping with the tumor suppressing func-
tions of its BRCA2 partner protein. New experiments with ad-
ditional Palb2 and Brca2 mutant mouse strains would be
required to distinguish between these possibilities.
Finally, tumor heterogeneity likely affected the CGH proﬁles
(Fig. S5) in ways that make it difﬁcult to identify regions of
chromosomal imbalances that were unique to Palb2/Trp53
tumors. Conceivably, a more comprehensive analysis with a much
larger collection of tumor samples would reveal such regions.
Loss of 53BP1 Fails to Rescue the HR Defect Caused by PALB2
Deﬁciency. Loss of 53BP1 can rescue the HR defect and lethal-
ity observed in either Brca1Δ11/Δ11 or Brca1-null cells and mice
(42–45). Similarly, decreased expression of the P53 binding pro-
tein 1 (53BP1) was detected in triple negative breast cancers as
well as human BRCA1 tumors (45). Therefore, we asked whether
Trp53bp1 (which encodes mouse 53BP1) expression is reduced in
Palb2/Trp53 KO tumors, and whether its absence rescues the HR
defect associated with Palb2 loss. Quantitative RT-PCR analysis of
Trp53bp1 mRNA in freshly isolated Palb2 breast tumor samples
Fig. 3. CGH analysis of Palb2 tumors. (A) Control (spleen) and tumor DNAs
were hybridized to whole genome arrays to determine regions of loss or gains
in mouse breast tumor samples. Representative rainbow graphs for each tu-
mor genotype showing log2 mean DNA relative dose ratio (tumor/spleen)
across the entire genome are presented. Each dot represents the average
signal from 10 ormore consecutive probes (or a segment of∼40 kb of genomic
DNA). The amplitude of the data points above or below the midline indicates
the extent of loss/gain in each segment, respectively. (B and C) Scatter plot
graphs indicating the relative dose of the deleted segments (log2 < −0.5, B)
and ampliﬁed segments (log2 > 0.5, C), each dot representing one segment.
The number of dots represents the number of segments for all tumors of the
relevant genotype, and the number of tumors analyzed (n) for Brca1/Trp53,
Brca2/Trp53, Trp53-only, and Palb2/Trp53 tumors were 4, 5, 7, and 8, re-
spectively. The horizontal lines are the average segment dose per genotype,
and the P values displayed correspond to the result of the nonparametric
Mann–Whitney–Wilcoxon signed-rank test, which followed the Kruskal–
Wallis one-way analysis of variance (P < 0.0001).
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showed that levels of Trp53bp1 messenger varied considerably
among the tumors that were analyzed. However, overall Trp53bp1
mRNA levels were not signiﬁcantly different in Palb2-deﬁcient
and Palb2-proﬁcient tumors (Fig. 4A).
To determine whether HR deﬁciency due to Palb2 loss is
complemented by Trp53bp1 loss in primary cells (cultured primary
splenic B cells), we generated Palb2ﬂ/ﬂ; CD19-Cre mice that were
or were not deﬁcient in Trp53bp1. Cultured primary splenocytes
from these mice were then assayed for HR competence upon
treatment with PARP inhibitors (PARPi), which selectively
induces DNA damage and chromosomal aberrations in HR-
deﬁcient cells (46). Treatment with KU0058948 (PARPi) led to an
accumulation of chromosomal and chromatid breaks, and radial
structures were evident in chromosomal spreads from cultured
Palb2ﬂ/ﬂ; Trp53bp1+/−; CD19-Cre primary splenocytes (Fig. 4B).
The number of chromosomal aberrations observed was not re-
duced in Palb2ﬂ/ﬂ; Trp53bp1−/−; CD19-Cre splenocytes, implying
that Trp53bp1 deletion did not complement the HR defect caused
by Palb2 deﬁciency (Fig. 4B). Trp53bp1 deletion also failed to
rescue the chromosomal aberrations found in spreads from PARPi-
treated Brca2ﬂ/ﬂ; Trp53bp1−/−; CD19-Cre splenocytes (Fig. S6A),
which appeared to be even more extensive than those observed in
PARPi-treated Palb2ﬂ/ﬂ; Trp53bp1−/−; CD19-Cre cells (Fig. 4B). As
has been previously described (43, 45), complete rescue of the DNA
repair deﬁciency in Brca1ﬂ/ﬂ; Trp53bp1−/−; CD19-Cre splenocytes
was observed (Fig. S6B).
Of note, both Palb2/Trp53bp1 and Brca2/Trp53bp1 compound
KO cells displayed more chromosomal aberrations after PARPi
exposure than Palb2 or Brca2 single mutants (Fig. 4B, Fig. S6A).
Thus, whereas Brca1, Palb2, and Brca2 manifest closely related,
even overlapping functions, loss of Palb2 or Brca2 also resulted in
a differentDNAdamage response afterTrp53bp1 elimination from
that manifested by Brca1 KO cells, in which Trp53bp1 codeletion
rescued the genomic instability observed after PARP inhibition.
These observations suggest that the contributions of PALB2
and BRCA2 to HR-based DSB repair are distinct from those of
BRCA1 and cannot be complemented by 53BP1 loss. In keeping
with existing evidence, PALB2 and BRCA2 may be de facto HR
effectors that cannot be replaced or bypassed, except by artiﬁ-
cially forcing the loading of RAD51 onto chromatin at/near
DSB, which 53BP1 loss has not yet been shown to promote (45,
47–49). These observations, along with earlier results (4), also
suggest that PARP inhibition might be a potential therapeutic
regimen in PALB2-deﬁcient tumors, as it is in BRCA1- and
BRCA2-associated tumors (46).
Conclusions
In summary, we have shown that Palb2 is a breast tumor sup-
pressor gene in mice as it is in humans and that it synergizes with
Trp53 to suppress tumor formation. The outcome of dual Palb2/
Trp53 nullizygosity in the mouse mammary gland is highly pen-
etrant breast cancer. In keeping with the fact that PALB2 is also
a breast tumor suppressor in humans, PALB2 might be viewed as
a BRCA3-like allele. Moreover, tumorigenesis driven by Palb2
loss in the mouse is not entirely suppressed on a Trp53WT germ-
line background, unlike most Brca1 and Brca2 mouse models of
breast tumorigenesis (50).
Despite many similarities to Brca2/Trp53 and Brca1/Trp53
breast tumors, Palb2 tumors displayed certain divergent genomic
features that might be viewed as separating them from BRCA1
and -2 cancers. Speciﬁcally, we observed patterns of genomic
aberrations that were different in Palb2/Trp53-derived tumors
from those detected in Brca1/Trp53- or Brca2/Trp53-derived
tumors. These data are consistent with the hypothesis that
PALB2 possesses biological functions that extend beyond
those of its major interactors, BRCA1 and BRCA2. Alterna-
tively, the effect of Palb2 deletion may mimic a phenotype akin
to partial loss of BRCA2, resulting in a less dramatic genomic
instability proﬁle in the relevant tumor cells.
Although the genomic instability of Brca1-deﬁcient cells can
be rescued by loss of Trp53bp1, deletion of the latter had, if
anything, an adverse effect in Palb2 KO cells. In that context,
Palb2 is more similar to Brca2, the absence of which leads to an
HR defect that also cannot be rescued by Trp53bp1 deletion.
Haploinsufﬁciency for Palb2 tumor suppression was not
detected in this model although one cannot rule out the possi-
bility that it would be manifest in a different model system and/or
with enlarged cohorts of experimental mice. For example, the
tumors in this mouse model driven by K14-Cre were uniformly of
the triple negative phenotype. This characteristic might well
contribute to the absence of haploinsufﬁciency in our system, in
the same way that BRCA1 mammary tumors derived from dis-
tinct cell populations display preferential patterns of consecutive
LOH events along the tumorigenesis pathway (32, 51).
We believe that this mouse model will be useful in understanding
how Palb2 serves its breast cancer suppression function.
Fig. 4. The HR defect in Palb2-deﬁcient cells and tumors. (A) qRT-PCR for
Trp53bp1 mRNA in freshly isolated tumor samples that are either Palb2-
proﬁcient (+/+ and +/−, n = 8) or Palb2-deﬁcient (−/−, n = 14). Horizontal
lines represent the average relative expression value and the P value asso-
ciated to this comparison (Mann–Whitney U test) is indicated. (B) Acute
chromosomal damage and genome instability observed in chromosome
spreads following PARPi treatment that are not rescued by Trp53bp1 de-
letion in Palb2ﬂ/ﬂ;CD19-Cre B lymphocytes. (C) Established Palb2/Trp53-de-
ﬁcient breast tumor cell lines (example shown in the Bottom panels) reveal
a defect in the recruitment of RAD51 to IRIF whereas Palb2 heterozygosity
does not impair the proper IRIF localization of RAD51 in breast tumor lines
(Middle panels). Both should be compared with a Palb2 WT control breast
tumor line (Top panels).
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Materials and Methods
ES Cell Derivation, Embryo Harvesting, and Tetraploid Complementation Assay.
Generation of the conditional allele for Palb2 and additional experimental
details are described in SI Material and Methods. Oligo sequences used are
described in Table S1. ES cell derivation was performed according to stan-
dard protocols (52). Pregnant mice from timed matings were killed at in-
dicated time points by CO2 asphyxiation following institutional guidelines.
Uterine horns and embryos were dissected under the microscope, and iso-
lated embryos were directly used for digestion, DNA extraction, and geno-
typing. Negative selection of Palb2 KO embryos was analyzed according to
the Hardy–Weinberg equilibrium model, using an online tool (http://ihg.gsf.
de/cgi-bin/hw/hwa1.pl). Tetraploid complementation assays were performed
as described (53). All experimental procedures involving mouse work were
approved by the Dana-Farber Cancer Institute Institutional Care and Use
Committee under Animal Protocol 07–011.
Tumorigenesis Studies. Mouse cohorts were monitored for tumor formation
biweekly. Mammary tumor formation was scoredwhen a palpable tumor of 1.0
cm in its greatest diameter could be detected, as previously described (27, 30).
Mice harboring tumors were humanely killedwhen the tumor diameter reached
2.0 cm in its greatest dimension. Mice that were otherwise severely diseased/
distressed were also killed according to institutional guidelines. Mantel–Cox
logrank testwas applied for comparisonof tumor-free survival ofmouse cohorts.
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